Abstract
Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood-2020-140820
Journal: Blood | Publication Date: Nov 5, 2020 |
Citations: 6 |
Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval
Join us for a 30 min session where you can share your feedback and ask us any queries you have